Acrux Limited Company Summary |
|
Acrux is a specialty pharmaceutical company, developing and commercialising a range of patented, patient-preferred healthcare products for global markets, using its innovative technology to administer drugs through the skin. Acrux's product pipeline includes treatments of hormonal deficiencies, pain, central nervous system disorders and a contraceptive. Acrux has also licensed its technology to Eli Lilly for veterinary healthcare products.
|
|
COMPANY DATA |
 |
Fax |
(03) 8379 0101 |
 |
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Biotechnology |
|
|
Listed |
2004/09/29 |
|
|
Homepage |
www.acrux.com.au |
|
| |
Key Developments: Acrux Limited
 |
Australian Market Report of June 22: Break the Losing Streak
JUNE 22, 2009 13:00 - Article Views: 7,763
Last Friday, the Australian shares ended higher for the first time in a week. The benchmark S&P/ASX200 index gained 7.5 points, or 0.19 per cent, to 3,899.6 points, and the broader All Ordinaries index advanced 7 points, or 0.18 per cent, at 3894.4 points. |
|
 |
Acrux Limited (ASX:ACR) and KV Pharmaceutical (NYSE:KV-A) Launch EVAMIST Skin Spray Drug Delivery Technology in US
APR 16, 2008 11:20 - Article Views: 3,330
Acrux (ASX: ACR)(PNK:ARUXF) today announced that Evamist(tm), the first product utilising its unique skin spray drug delivery technology, has been launched by US licensee KV Pharmaceutical Company (NYSE: KVa/KVb) into one of the largest therapeutic categories in women's healthcare. |
|
11,346 COMPANY PROFILE VIEWS |
|
This Page Viewed: (Last 7 Days: 10) (Last 30 Days: 59) (Since Published: 2014)
|
|
|
|
ASX S&P200
ASX:ACR
